| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
118,506,000 |
| Market
Cap: |
450.32(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.65 - $8.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.7 |
| Insider 3/6 Months : 8.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
44,630 |
44,630 |
471,648 |
| Total Buy Value |
$0 |
$166,024 |
$166,024 |
$2,724,191 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
6 |
| Total Shares Sold |
4,296 |
78,990 |
96,836 |
590,364 |
| Total Sell Value |
$28,258 |
$301,730 |
$380,390 |
$5,527,958 |
| Total People Sold |
1 |
4 |
6 |
14 |
| Total Sell Transactions |
2 |
9 |
14 |
36 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2024-03-04 |
4 |
AS |
$7.77 |
$19,013 |
D/D |
(2,447) |
101,479 |
|
-32% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2024-01-29 |
4 |
AS |
$5.00 |
$9,245 |
D/D |
(1,849) |
103,926 |
|
-16% |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2024-01-09 |
4 |
S |
$4.38 |
$49,367 |
D/D |
(11,271) |
158,069 |
|
12% |
|
| Wolchko J Scott |
President and CEO |
• • – |
2024-01-09 |
4 |
S |
$4.37 |
$62,889 |
D/D |
(14,391) |
371,248 |
|
12% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2024-01-09 |
4 |
S |
$4.37 |
$47,519 |
D/D |
(10,874) |
142,361 |
|
12% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2024-01-09 |
4 |
S |
$4.37 |
$30,712 |
D/D |
(7,028) |
105,775 |
|
12% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2024-01-02 |
4 |
AS |
$3.66 |
$18,966 |
D/D |
(5,182) |
112,803 |
|
30% |
|
| Green Jeremy |
Director |
– • • |
2023-12-26 |
4 |
B |
$3.72 |
$166,024 |
I/I |
44,630 |
13,180,388 |
2.25 |
4% |
|
| Green Jeremy |
Director |
– • • |
2023-12-26 |
4 |
A |
$3.72 |
$6,157,976 |
I/I |
1,655,370 |
13,135,758 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2023-12-26 |
4 |
D |
$3.72 |
$6,157,976 |
I/I |
(1,655,370) |
13,135,758 |
|
- |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2023-12-18 |
4 |
AS |
$3.50 |
$5,548 |
D/D |
(1,585) |
117,985 |
|
52% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2023-11-09 |
4 |
AS |
$2.40 |
$58,471 |
D/D |
(24,363) |
153,235 |
|
249% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2023-08-18 |
4 |
S |
$2.80 |
$13,210 |
D/D |
(4,718) |
119,570 |
|
-32% |
|
| Xu Yuan |
Director |
– • – |
2023-08-04 |
4 |
AS |
$3.71 |
$2,345 |
D/D |
(632) |
9,302 |
|
-36% |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2023-07-05 |
4 |
S |
$4.87 |
$18,769 |
D/D |
(3,854) |
41,146 |
|
56% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2023-07-05 |
4 |
AS |
$4.83 |
$25,029 |
D/D |
(5,182) |
124,288 |
|
-56% |
|
| Xu Yuan |
Director |
– • – |
2023-06-14 |
4 |
AS |
$5.58 |
$19,307 |
D/D |
(3,460) |
9,934 |
|
-67% |
|
| Green Jeremy |
Director |
– • • |
2023-04-21 |
4 |
B |
$6.18 |
$1,586,029 |
I/I |
256,639 |
13,135,758 |
2.25 |
-58% |
|
| Green Jeremy |
Director |
– • • |
2023-04-20 |
4 |
B |
$5.99 |
$119,800 |
I/I |
20,000 |
12,879,119 |
2.25 |
-55% |
|
| Chu Yu-Waye |
Chief Medical Officer |
• – – |
2023-04-18 |
4 |
S |
$6.52 |
$16,648 |
D/D |
(2,532) |
140,676 |
|
58% |
|
| Green Jeremy |
Director |
– • • |
2023-04-14 |
4 |
B |
$6.00 |
$154,200 |
I/I |
25,700 |
12,859,119 |
2.25 |
-55% |
|
| Green Jeremy |
Director |
– • • |
2023-04-14 |
4 |
A |
$5.84 |
$32,075,528 |
I/I |
5,492,385 |
12,833,419 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2023-04-14 |
4 |
D |
$5.84 |
$32,075,528 |
I/I |
(5,492,385) |
12,833,419 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2023-04-14 |
4 |
S |
$5.84 |
$1,765,660 |
I/I |
(302,339) |
12,833,419 |
|
55% |
|
| Green Jeremy |
Director |
– • • |
2023-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
167,205 |
13,135,758 |
|
- |
|
297 Records found
|
|
Page 1 of 12 |
|
|
0.07 (1.81%) 
